Canada · Delayed Price · Currency is CAD BioSyent Statistics
Total Valuation
BioSyent has a market cap or net worth of CAD 160.71 million. The enterprise value is 155.06 million.
| Market Cap | 160.71M |
| Enterprise Value | 155.06M |
Important Dates
The next estimated earnings date is Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
BioSyent has 11.44 million shares outstanding. The number of shares has decreased by -1.64% in one year.
| Current Share Class | 11.44M |
| Shares Outstanding | 11.44M |
| Shares Change (YoY) | -1.64% |
| Shares Change (QoQ) | +0.77% |
| Owned by Insiders (%) | 9.96% |
| Owned by Institutions (%) | 19.50% |
| Float | 9.21M |
Valuation Ratios
The trailing PE ratio is 17.92 and the forward PE ratio is 14.99.
| PE Ratio | 17.92 |
| Forward PE | 14.99 |
| PS Ratio | 3.50 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 8.21 |
| P/FCF Ratio | 12.96 |
| P/OCF Ratio | 12.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.21, with an EV/FCF ratio of 12.50.
| EV / Earnings | 17.16 |
| EV / Sales | 3.37 |
| EV / EBITDA | 12.21 |
| EV / EBIT | 13.34 |
| EV / FCF | 12.50 |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.12.
| Current Ratio | 1.89 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 0.42 |
| Interest Coverage | 171.30 |
Financial Efficiency
Return on equity (ROE) is 22.31% and return on invested capital (ROIC) is 32.61%.
| Return on Equity (ROE) | 22.31% |
| Return on Assets (ROA) | 13.81% |
| Return on Invested Capital (ROIC) | 32.61% |
| Return on Capital Employed (ROCE) | 25.31% |
| Weighted Average Cost of Capital (WACC) | 7.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.35 |
Taxes
In the past 12 months, BioSyent has paid 3.12 million in taxes.
| Income Tax | 3.12M |
| Effective Tax Rate | 25.68% |
Stock Price Statistics
The stock price has increased by +22.99% in the last 52 weeks. The beta is 0.64, so BioSyent's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | +22.99% |
| 50-Day Moving Average | 14.24 |
| 200-Day Moving Average | 13.25 |
| Relative Strength Index (RSI) | 63.31 |
| Average Volume (20 Days) | 12,544 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSyent had revenue of CAD 45.98 million and earned 9.04 million in profits. Earnings per share was 0.78.
| Revenue | 45.98M |
| Gross Profit | 34.79M |
| Operating Income | 11.63M |
| Pretax Income | 12.16M |
| Net Income | 9.04M |
| EBITDA | 12.55M |
| EBIT | 11.63M |
| Earnings Per Share (EPS) | 0.78 |
Balance Sheet
The company has 10.90 million in cash and 5.25 million in debt, with a net cash position of 5.65 million or 0.49 per share.
| Cash & Cash Equivalents | 10.90M |
| Total Debt | 5.25M |
| Net Cash | 5.65M |
| Net Cash Per Share | 0.49 |
| Equity (Book Value) | 44.99M |
| Book Value Per Share | 3.93 |
| Working Capital | 14.76M |
Cash Flow
In the last 12 months, operating cash flow was 12.45 million and capital expenditures -47,351, giving a free cash flow of 12.40 million.
| Operating Cash Flow | 12.45M |
| Capital Expenditures | -47,351 |
| Depreciation & Amortization | 921,751 |
| Net Borrowing | 3.76M |
| Free Cash Flow | 12.40M |
| FCF Per Share | 1.08 |
Margins
Gross margin is 75.67%, with operating and profit margins of 25.28% and 19.65%.
| Gross Margin | 75.67% |
| Operating Margin | 25.28% |
| Pretax Margin | 26.44% |
| Profit Margin | 19.65% |
| EBITDA Margin | 27.29% |
| EBIT Margin | 25.28% |
| FCF Margin | 26.97% |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 1.57%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 1.57% |
| Dividend Growth (YoY) | 10.53% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 25.54% |
| Buyback Yield | 1.64% |
| Shareholder Yield | 3.20% |
| Earnings Yield | 5.62% |
| FCF Yield | 7.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioSyent has an Altman Z-Score of 7.12 and a Piotroski F-Score of 4.
| Altman Z-Score | 7.12 |
| Piotroski F-Score | 4 |